|Bid||133.55 x 200|
|Ask||133.59 x 200|
|Day's Range||132.56 - 134.44|
|52 Week Range||94.42 - 135.18|
|PE Ratio (TTM)||50.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.
With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.
Agio Pharmaceuticals saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia.